In the Phase III VISIONARY study, sibeprenlimab, an investigational monoclonal antibody, showed a 51.2% reduction in ...

Otsuka's investigational antibody sibeprenlimab approximately halved levels of this key biomarker in patients with ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

Mediar Therapeutics has dosed the first subject in the Phase II WISPer trial of its investigational therapy, MTX-463, for ...

A new trial finds that intravenous immunoglobulin stabilises kidney function and slows damage in patients with chronic ...

Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™ fully ...

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

The following is a summary of “Fluctuations in serum aquaporin-4 antibody titers: the clinical significance in neuromyelitis ...

Sibeprenlimab targets a protein called A proliferation-inducing ligand (APRIL), and the drug is designed to limit the ...

Researchers from the Shenzhen Institutes of Advanced Technology (SIAT), Chinese Academy of Sciences, along with multiple ...

As CIDP moves toward targeted therapies and patient-friendly regimens, the market is primed for disruption—offering a fresh ...